Shares of Zydus Lifesciences Limited saw a modest rise, closing at ₹963.30, a 1.43% increase from the previous close of ₹949.75. This increase led to a gain of around ₹1,363.45 crore in the company’s market capitalization.
As of today’s trading session, Zydus Lifesciences’ market cap stands at ₹96,930.52 crore. The stock opened at ₹958.35, reached a high of ₹968.95, and a low of ₹946.85, reflecting steady trading activity.
Brokerage Initiation and Analyst Insights
Jefferies has retained its ‘buy’ rating on Zydus Lifesciences, while revising the target price from ₹1,450 to ₹1,380, suggesting a potential 45% upside from the current market price of ₹948.95. The company’s Q2 results were positive, beating estimates due to improved margins.
Key Trading Information
- Traded Volume: 16.75 lakh shares
- Traded Value: ₹160.90 crore
- Deliverable Percentage: 28.94%
Price Information
- 52-Week High: ₹1,324.30 (as of 09-Aug-2024)
- 52-Week Low: ₹616.05 (as of 13-Nov-2023)
- Upper Price Band: ₹1,044.70
- Lower Price Band: ₹854.80
Additional Security Information
- Status: Listed
- Date of Listing: 18-Apr-2000
- Index: Nifty Next 50
- Industry: Pharmaceuticals
The consistent growth in Zydus Lifesciences’ share price, along with positive brokerage coverage, highlights a strong investor sentiment towards the stock.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
